The type 2 asthma mediator IL-13 inhibits SARS-CoV-2 infection of bronchial epithelium.

Luke R BonserWalter L EckalbarLauren RodriguezJiangshan ShenKyung Duk KohLorna T ZlockStephanie ChristensonPrescott G WoodruffWalter E FinkbeinerDavid J Erle

Published in: bioRxiv : the preprint server for biology (2021)

IL-13 markedly reduces susceptibility of HBECs to SARS-CoV-2 infection through mechanisms that likely differ from those activated by type I interferons. Our findings may help explain reports of relatively low prevalence of asthma in patients diagnosed with COVID-19 and could lead to new strategies for reducing SARS-CoV-2 infection.

Keyphrases

respiratory syndrome coronavirus
chronic obstructive pulmonary disease
end stage renal disease
sars cov
coronavirus disease
lung function
ejection fraction
newly diagnosed
allergic rhinitis
risk factors
peritoneal dialysis
patient reported outcomes
cystic fibrosis
electronic health record